Increasing Resistance to Extended-Spectrum Cephalosporins, Fluoroquinolone, and Carbapenem in Gram-Negative Bacilli and the Emergence of Carbapenem Non-Susceptibility in Klebsiella pneumoniae: Analysis of Korean Antimicrobial Resistance Monitoring System (KARMS) Data From 2013 to 2015 by 源��룄洹� et al.
ISSN 2234-3806 • eISSN 2234-3814 
https://doi.org/10.3343/alm.2017.37.3.231 www.annlabmed.org  231
Ann Lab Med 2017;37:231-239
https://doi.org/10.3343/alm.2017.37.3.231
Original Article
Clinical Microbiology
Increasing Resistance to Extended-Spectrum 
Cephalosporins, Fluoroquinolone, and Carbapenem in 
Gram-Negative Bacilli and the Emergence of Carbapenem 
Non-Susceptibility in Klebsiella pneumoniae: Analysis 
of Korean Antimicrobial Resistance Monitoring System 
(KARMS) Data From 2013 to 2015
Dokyun Kim, M.D.1, Ji Young Ahn, M.D.2, Chae Hoon Lee, M.D.3, Sook Jin Jang, M.D.4, Hyukmin Lee, M.D.1,  
Dongeun Yong, M.D.1, Seok Hoon Jeong, M.D.1, and Kyungwon Lee, M.D.1
Department of Laboratory Medicine and Research Institute of Bacterial Resistance1, Yonsei University College of Medicine, Seoul; Department of Laboratory 
Medicine2, Soonchunhyang University College of Medicine, Cheonan; Department of Laboratory Medicine3, College of Medicine, Yeungnam University 
College of Medicine, Daegu; Department of Laboratory Medicine4, Chosun University College of Medicine, Gwangju, Korea
Background: National surveillance of antimicrobial resistance becomes more important 
for the control of antimicrobial resistance and determination of treatment guidelines. We 
analyzed Korean Antimicrobial Resistance Monitoring System (KARMS) data collected from 
2013 to 2015.
Methods: Of the KARMS participants, 16 secondary or tertiary hospitals consecutively re-
ported antimicrobial resistance rates from 2013 to 2015. Data from duplicate isolates and 
institutions with fewer than 20 isolates were excluded. To determine the long-term trends, 
previous KARMS data from 2004 to 2012 were also considered.
Results: The prevalence of methicillin-resistant Staphylococcus aureus and vancomycin-
resistant Enterococcus faecium from 2013 to 2015 was 66–72% and 29–31%, respec-
tively. The resistance rates of Escherichia coli to cefotaxime and cefepime gradually in-
creased to 35% and 31%, respectively, and fluoroquinolone resistance reached 48% in 
2015. The resistance rates of Klebsiella pneumoniae to cefotaxime, cefepime, and car-
bapenem were 38–41%, 33–41%, and <0.1–2%, respectively, from 2013 to 2015. The 
carbapenem susceptibility rates of E. coli and K. pneumoniae decreased from 100% and 
99.3% in 2011 to 99.0% and 97.0% in 2015, respectively. The resistance rate of Pseudo-
monas aeruginosa to carbapenem increased to 35% and the prevalence of carbapenem-
resistant Acinetobacter baumannii increased from 77% in 2013 to 85% in 2015.
Conclusions: Between 2013 and 2015, the resistance rates of E. coli to third- and fourth-
generation cephalosporins increased continuously, while carbapenem-susceptibility grad-
ually decreased, particularly in K. pneumoniae. The prevalence of carbapenem-resistant 
P. aeruginosa and A. baumannii increased significantly; therefore, few treatment options 
remain for these resistant strains.
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INTRODUCTION
The prevalence of antimicrobial-resistant bacteria has increased 
worldwide. In 2013, the Centers for Disease Control and Preven-
tion in the United States reported that each year, at least two mil-
lion people in the United States acquire serious infections due 
to resistant bacteria and that over 23,000 people die as a direct 
result of these antibiotic-resistant infections [1]. Resistance rates 
vary across countries because of differences in antimicrobial 
agent usage and systems for the prevention of antimicrobial re-
sistant bacteria. In addition to resistance rates, modes of resis-
tance also differ among countries and even among cities within 
the same country. Therefore, accurate nationwide surveillance 
of antimicrobial-resistant bacteria is becoming more important 
for the establishment of treatment guidelines for optimal applied 
therapies.
The spread of antimicrobial resistance is a major concern in 
Korea. In 2003, the prevalence of resistance in bacterial strains 
included 66% methicillin-resistant Staphylococcus aureus (MRSA), 
22% vancomycin-resistant Enterococcus faecium, 14% ceftazi-
dime-resistant Klebsiella pneumoniae, and 25% imipenem-re-
sistant Pseudomonas aeruginosa [2]. Lee et al [3] reported that 
according to the Korean Nationwide Surveillance of Antimicro-
bial Resistance (KONSAR) study, the prevalence of ceftazidime-
resistant K. pneumoniae and imipenem-resistant Acinetobacter 
species increased up to 47% and 22%, respectively. In 2009, 
the prevalence of imipenem-resistant Acinetobacter species in-
creased to 57% [4]. Recently, carbapenem-resistant Enterobac-
teriaceae (CRE) have been increasingly reported in many hospi-
tals in Korea, mostly associated with the clonal expansion of K. 
pneumoniae carbapenemase [5]. The Korean government has 
implicated six multidrug-resistant organisms, including MRSA, 
vancomycin-resistant Staphylococcus aureus (VRSA), vancomy-
cin-resistant enterococci, multidrug-resistant P. aeruginosa, and 
multidrug-resistant Acinetobacter baumannii (MRAB), as the 
main agents of nosocomial infections. Since 2012, Korean hos-
pitals are required to report infections by these organisms to the 
Korea Centers for Disease Control and Prevention (http://www.
cdc.go.kr/CDC/). However, this program focuses solely on anti-
microbial resistance rates and not on particular strain differences; 
further evaluation for elucidating the mode of resistance is not 
available through this program.
The Korean Antimicrobial Resistance Monitoring System (KA-
RMS), which has been overseen by the Korea Centers for Dis-
ease Control and Prevention since 2002, is a surveillance pro-
gram for collecting antimicrobial resistance data in Korea as well 
as a limited number of resistant strain isolates. A total of 35 ter-
tiary and secondary hospitals participate in this program by re-
porting the antimicrobial resistance rates of various bacteria once 
a year. In this study, we evaluated the antimicrobial resistance 
rates of the most commonly isolated bacteria, including S. au-
reus, Enterococcus species, Streptococcus pneumoniae, Esch-
erichia coli, K. pneumoniae, P. aeruginosa, and A. baumannii, 
on the basis of the data from 16 hospitals that continuously re-
ported to KARMS between 2013 and 2015.
METHODS
Antimicrobial resistance data was collected from 31 secondary 
or tertiary hospitals; 16 of these hospitals reported annually from 
2013 to 2015. These 16 hospitals (620–1,356 beds) covered 
eight major cities and provinces in Korea, representing national 
antimicrobial resistance trends. The hospitals used their own 
hospital system or WHONET software [6] and duplicate isolates 
were excluded from the analysis. Antimicrobial susceptibility 
tests were performed by using disk diffusion or modified broth 
microdilution tests with the VITEK 2 automated system (bioMéri-
eux, Marcy l’Etoile, France) or the MicroScan system (Beckman 
Coulter, Brea, CA, USA) according to the CLSI guidelines [7]. If 
the CLSI guideline threshold was not available, the European 
Committee on Antimicrobial Susceptibility Testing (EUCAST) 
threshold was applied for the determination of susceptibility. To 
minimize size difference bias between the hospitals, data con-
sisting of less than 20 isolates of an organism were excluded; 
resistance rates were calculated as the median and range be-
cause of the limited number of hospitals. The antimicrobial re-
sistance of gram-negative bacilli was compared with previous 
results from 2004 to determine long-term trend changes [8-10].
RESULTS
1. Antimicrobial resistance in gram-positive cocci
The resistance rates of gram-positive cocci from 2013 to 2015 
are summarized in Table 1. The prevalence of MRSA decreased 
from 72% in 2013 to 66% in 2015. The resistance rates of S. 
aureus isolates to other antibiotics also slightly decreased from 
2013; 95% for penicillin, 54% for erythromycin, 54% for 
clindamycin, and 48% for ciprofloxacin in 2015. Over 97% of 
the isolates showed susceptibility to trimethoprim-sulfamethoxa-
zole, while no vancomycin- and/or teicoplanin-resistant S. au-
reus were isolated. The rates of penicillin resistance in S. pneu-
moniae ranged from 11–14%; and 9–12% of isolates were re-
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sistant to levofloxacin. In Enterococcus faecalis, ampicillin resis-
tance was low (0–2%); however, 61% and 18% of isolates were 
resistant to high-level gentamicin (minimum inhibitory concen-
tration [MIC] >500 μg/mL) and high-level streptomycin (MIC 
>1,000 μg/mL), respectively. The rates of vancomycin resistance 
were 0.8–1% in both 2013 and 2015. In contrast, ampicillin re-
sistance was widespread in E. faecium (93–94%) and 29–31% 
of isolates exhibited vancomycin resistance during the test period.
Table 1. Antimicrobial resistance rates (%) of gram-positive cocci 
Organism Antimicrobial agent
Antimicrobial resistance rate, median (range)
2013 2014 2015
Staphylococcus aureus N of tested isolates 18,461 13,017 10,770
Penicillin 95 (84–99) 95 (93–98) 95 (90–100)
Oxacillin 72 (54–80) 70 (46–85) 66 (40–84)
Erythromycin 63 (44–73) 61 (41–73) 54 (38–70)
Clindamycin 63 (31–72) 56 (32–71) 54 (30–71)
Gentamicin 49 (29–60) 48 (24–65) 42 (25–67)
Ciprofloxacin 59 (28–67) 54 (28–68) 48 (24–66)
Tetracycline 54 (30–70) 54 (25–66) 48 (27–68)
Trimethoprim-sulfamethoxazole 2 (0.4–4) 3 (1–6) 3 (1–4)
Vancomycin 0 0 0
Teicoplanin 0 0 0
Linezolid <0.1 (0–0.6) <0.1 (0–3) <0.1 (0–1)
Streptococcus pneumoniae N of tested isolates 1,007 865 890
Penicillin G 12 (0–16) 14 (3–18) 11 (0–18)
Erythromycin 80 (65–87) 81 (68–91) 82 (67–100)
Fluoroquinolone 9 (0–24) 12 (4–22) 11 (0–24)
Enterococcus faecalis N of tested isolates 7,799 5,590 4,945
Ampicillin 1 (0–3) 2 (0–6) 0 (0–6)
High-level gentamicin* 62 (31–67) 59 (33–67) 61 (52–68)
High-level streptomycin* 22 (18–35) 19 (13–30) 18 (7–26)
Ciprofloxacin 36 (18–47) 34 (19–47) 36 (17–64)
Tetracycline 88 (92–93) 88 (79–92) 89 (83–96)
Vancomycin 1 (0–8) 1 (0–7) 0.8 (0–16)
Teicoplanin 0.9 (0–10) 1 (0–7) 0.9 (0–6)
Linezolid 0.3 (0–2.0) 0.6 (0–2.0) 0.6 (0–2)
Enterococcus faecium N of tested isolates 5,536 4,539 4,392
Ampicillin 94 (89–97) 93 (76–99) 93 (82–98)
High-level gentamicin* 58 (32–74) 59 (42–75) 53 (40–80)
High-level streptomycin* 34 (16–44) 23 (16–51) 24 (11–34)
Ciprofloxacin 94 (90–99) 95 (77–99) 95 (84–98)
Tetracycline 36 (21–54) 31 (23–50) 31 (17–55)
Vancomycin 29 (12–68) 31 (19–46) 30 (15–49)
Teicoplanin 23 (9–56) 28 (15–69) 26 (12–45)
Linezolid 0.2 (0–4.0) 0.0 (0–1.0) 0.0 (0–2.0)
Quinupristin-dalfopristin 1.0 (0–4.0) 0.6 (0–5.0) 0.6 (0–11.0)
*High level resistance of gentamicin and streptomycin were defined as above the minimum inhibitory concentration (MIC) of 500 and 1,000 μg/mL, respec-
tively. 
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2. Antimicrobial resistance in Enterobacteriaceae
The antimicrobial resistance rates of Enterobacteriaceae are de-
tailed in Table 2. The resistance rates of E. coli isolates were 69–
72% to ampicillin, 29–35% for cefotaxime, 30–31% for ceftazi-
dime, 28–31% for cefepime, and 9–10% for cefoxitin from 2013 
to 2015, respectively. The resistance rates to fluoroquinolone in-
Table 2. Antimicrobial resistance rates (%) of Escherichia coli and Klebsiella pneumoniae in Korea from 2013 to 2015*
Antimicrobial agent
E. coli K. pneumoniae
2013 (26,339) 2014 (18,317) 2015 (16,262) 2013 (10,548) 2014 (7,867) 2015 (6,571)
Ampicillin 70 (66–79) 69 (16 –82) 72 (51–79) NT NT NT
Piperacillin 79 (74–84) 69 (67–74) 68 (67–69) NT NT NT
Ampicillin-sulbactam 40 (27–69) 44 (29–53) 45 (13–48) NT NT NT
Piperacillin-tazobactam 6 (4–9) 5 (2–10) 5 (2–9) 22 (10–38) 20 (6–36) 21 (2–36)
Cefotaxime 29 (21–41) 32 (24–44) 35 (23–46) 40 (22–62) 41 (20–57) 38 (25–60)
Ceftazidime 30 (9–42) 31 (13–45) 31 (11–46) 40 (15–62) 41 (18–57) 36 (21–60)
Cefepime 28 (5–42) 30 (6–42) 31 (41) 38 (6–61) 41 (6–57) 33 (11–59)
Aztreonam 30 (13–42) 30 (13–45) 30 (14–47) 39 (17–62) 38 (17– 57) 35 (24–60)
Cefoxitin 9 (6–14) 10 (6–13) 9 (6–16) 17 (11–29) 12 (9–26) 14 (10–25)
Imipenem <0.1 (0–1) <0.1 (0–1) <0.1 (0–1) <0.1 (0–3) 1 (0–10) 1 (0–10)
Meropenem <0.1 (0–6) <0.1 (0–2) <0.1 (0–2) <0.1 (0–3) 1 (0–11) 1 (0–10)
Amikacin 1 (0–2) 1 (0–2) 1 (0–1) 7 (2–16) 5 (1–31) 5 (1–25)
Gentamicin 29 (25–39) 30 (22–42) 29 (25–36) 19 (11–32) 20 (8–34) 19 (8–32)
Fluoroquinolone 42 (32–59) 45 (32–55) 48 (34–57) 34 (16–55) 35 (16–46) 34 (18–50)
Cotrimoxazole 38 (34 –45) 38 (34–40) 39 (34–46) 21 (9–42) 24 (18–73) 30 (23–45)
Tigecycline NT NT NT 5 (1–15) 6 (4–14) 8 (0–22)
*Antimicrobial resistance rates are presented as median (whole range).
Abbreviation: NT, not tested.
Fig. 1. Antimicrobial resistance rates (%) of Escherichia coli and Klebsiella pneumoniae from 2004 to 2015. The resistance rates from 2004 
to 2012 were from the previous publication of the KARMS [8-10]. The resistance rates of E. coli to fluoroquinolone, third- and fourth-gener-
ation cephalosporins (CAZ, CTX, FEP) gradually increased since 2004. However, the resistance rates of E. coli and K. pneumonia to cepha-
mycin decreased. The vertical dotted lines indicate the application of the lowered cefotaxime and ceftazidime breakpoints according to chan-
ges in the CLSI guideline in 2010. 
Abbreviations: CAZ, ceftazidime; CTX, cefotaxime; FEP, cefepime; FOX, cefoxitin; FQ, fluoroquinolone.
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creased from 42% in 2013 to 48% in 2015, while the resistance 
rate to trimethoprim-sulfamethoxazole remained stable at 38–
39%. In K. pneumoniae, the resistance rates to third- and fourth-
generation cephalosporins were 36–41% and 33–41%, respec-
tively. The resistance rates were 12–17% for cefoxitin, 34–35% 
for fluoroquinolone, and 21–30% for trimethoprim-sulfamethox-
azole. Over the last decade, the rates of resistance to the third- 
and fourth-generation cephalosporins and fluoroquinolone have 
steadily increased, except resistance to cefoxitin, which decre-
ased significantly (Fig. 1). The resistance rate to carbapenems 
in E. coli and K. pneumoniae was 0.1% in 2013 and 0.1% and 
1%, respectively, in 2015. However, the susceptibility rates in 
both species decreased from 99.7% and 98.7% in 2013 to 99.3% 
and 97.0% in 2015, respectively (Fig. 2). 
3.  Antimicrobial resistance in glucose non-fermenting  
gram-negative bacilli
The antimicrobial resistance rates of A. baumannii and P. aeru-
ginosa are shown in Table 3. The resistance rates of A. bauman-
nii were 77–86% for extended-spectrum cephalosporins, 77–
85% for carbapenems, 84–88% for fluoroquinolone, 45–60% 
for amikacin, and 73–76% for gentamicin. The resistance rate 
to ampicillin-sulbactam decreased from 57% in 2013 to 46% in 
2015. The resistance rates were 2–5% for tigecycline and less 
than 0.1% for colistin. In P. aeruginosa, the resistance rates to 
ceftazidime, cefepime, amikacin, and gentamicin were 19–21%, 
18–20%, 12–13%, and 18–20%, respectively. The resistance 
rate of carbapenem-resistant P. aeruginosa from 2013 to 2015 
Table 3. Antimicrobial resistance rates (%) of Acinetobacter baumannii and Pseudomonas aeruginosa in Korea from 2013 to 2015*
Antimicrobial agent
A. baumannii P. aeruginosa
2013 (11,117) 2014 (10,288) 2015 (9,345) 2013 (9,703) 2014 (6,919) 2015 (5,259)
Piperacillin 82 (60–100) 87 (66–97) 86 (76–97) 30 (14–49) 26 (14–46) 27 (16–46)
Ampicillin-sulbactam 57 (16–76) 50 (24–91) 46 (16–75) NT NT NT
Piperacillin-tazobactam 81 (56–100) 86 (71–100) 82 (69–96) 29 (2–54) 28 (14–50) 25 (7–45)
Cefotaxime 79 (56–100) 86 (71–97) 84 (65–100) NT NT NT
Ceftazidime 77 (51–93) 84 (55–97) 83 (56–96) 21 (6–39) 21 (8–37) 19 (9–40)
Cefepime 78 (55–93) 85 (70–97) 83 (67–96) 20 (6–34) 20 (7–37) 18 (6–37)
Aztreonam NT NT NT 23 (13–51) 33 (10–68) 23 (13–38)
Imipenem 77 (54–92) 84 (70–96) 85 (73–97) 32 (12–57) 35 (16–50) 35 (15–47)
Meropenem 77 (55–93) 85 (66–96) 84 (67–96) 24 (10–46) 27 (12–40) 25 (15–45)
Amikacin 45 (3–79) 52 (12–83) 60 (8–89) 13 (4–25) 12 (6–59) 13 (6–47)
Gentamicin 73 (42–88) 76 (52–89) 75 (42–90) 19 (7–32) 20 (7–37) 18 (5–37)
Ciprofloxacin 84 (59–96) 88 (74–98) 87 (75–97) 36 (15–53) 30 (20–48) 34 (17–47)
Cotrimoxazole 74 (43–97) 75 (58–88) 64 (52–75) NT NT NT
Tigecycline 5 (0–12) 2 (1–7) 4 (0–7) NT NT NT
Colistin <0.1 (0–2) <0.1 (0–1) <0.1 (0–1) 1 (0–5) 1 (0–9) <0.1 (0–3)
*Antimicrobial resistance rates are presented as median (whole range).
Abbreviation: NT, not tested.
Fig. 2. Carbapenem susceptibility rates of Escherichia coli and Kleb­
siella pneumoniae from 2011 to 2015. The resistance rates from 
2011 to 2012 were from the previous publication of the KARMS [10].
Abbreviations: ECO, E. coli; KPN, K. pneumoniae; S, susceptible.
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was 32–35% for imipenem and 24–27% for meropenem (Fig. 
3). The resistance rates of A. baumannii showed a steady incre-
ase, except for ampicillin-sulbactam, while the resistance rates 
of P. aeruginosa exhibited a decrease, except for imipenem. 
DISCUSSION
The prevalence of antimicrobial-resistant organisms varies greatly 
among hospitals and countries. Moreover, changes in resistance 
rates differ greatly depending on time and region. For example, 
Scandinavian countries, such as Sweden, show low MRSA lev-
els (<1%) [11]. However, the rates of MRSA in other European 
countries, Japan, and Korea are as high as 40–60% [4, 12]. There-
fore, national surveillance systems are becoming more impor-
tant for guiding clinicians in terms of empirical treatment for sus-
pected infections and the control of antimicrobial resistance dis-
semination. KARMS data allowed us to analyze national trends 
of antimicrobial resistance and detect the emergence of new re-
sistances in Korea. 
MRSA is the one of the most important resistant pathogens; 
we found that the rate of MRSA slightly decreased from a peak 
of 75% in 2009 to 66% (55% in blood isolates, data not shown) 
in 2015 [4]. The prevalence of MRSA infection could be affected 
by carriage rate and healthcare-associated infection control; in 
addition, this decrease might be due to the introduction of the 
decolonization and hand-hygiene program (the most common 
transmission route of MRSA [13]) for controlling infection in health-
care-associated settings in Korea [14]. Vancomycin and teico-
planin are drugs commonly used for MRSA treatment; however, 
none of the S. aureus isolates showed vancomycin resistance 
between 2013 and 2015 and most isolates exhibited suscepti-
bility to linezolid. 
In S. pneumoniae, the resistance rate to penicillin G ranged 
from 11% to 14% during 2014 and 2015, which is similar to 
previous results following the application of a new breakpoint 
[15]. However, the resistance rate to erythromycin remained 
high (>80%) in 2015. A recent survey of the empirical treat-
ment of community-acquired pneumonia in Korea reported that 
13.4% of local clinic doctors still prescribe macrolide monother-
apy [16]; increased resistance to erythromycin could be the re-
sult of treatment failure due to this regimen. The resistance rate 
to fluoroquinolone was as low as 9–12%; however, this did rep-
resent an increase from the 2–5% reported in 2005 and 2006 
[17]. Previous use of fluoroquinolones, cerebrovascular disease, 
and healthcare-associated infection have been significantly as-
sociated with levofloxacin resistance in S. pneumoniae [18]; thus, 
antimicrobial stewardship and an infection control program are 
required to prevent the spread of fluoroquinolone-resistance. 
Resistance rates varied among Enterococcus species. In E. 
faecalis, the resistance rates were extremely low, 0–2% to ampi-
Fig. 3. Antimicrobial resistance rates (%) of Acinetobacter baumannii and Pseudomonas aeruginosa from 2004 to 2015. The resistance 
rates from 2004 to 2012 were from the previous publication of the KARMS [8-10].
Abbreviations: CAZ, ceftazidime; FEP, cefepime; FQ, fluoroquinolone; IMP, imipenem; MEM, meropenem; Amp-Sul, ampicillin-sulbactam.
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cillin and 1% to vancomycin, which is consistent with previous 
results since 2004 [8-10]. E. faecium showed a high prevalence 
of ampicillin resistance (> 90%) and the resistance rates to van-
comycin and teicoplanin were 30% and 26%, respectively. The 
similarity in the resistance rates to teicoplanin and vancomycin 
might indicate that most isolates contain vanA gene clusters; 
the small discrepancy could be related to the presence of the 
vanA gene with a VanB phenotype [19]. The resistance rates of 
E. faecium to linezolid and quinupristin/dalfopristin did not in-
crease during the surveillance period. The linezolid susceptibil-
ity of most isolates can be explained by the fact that the most 
common mechanism of linezolid resistance is a mutation in the 
linezolid binding site, which cannot be spread by horizontal trans-
fer, in contrast to the acquisition of the cfr gene. Persistent dap-
tomycin susceptibility (data not shown) might be caused by the 
unavailability of this antimicrobial agent in Korea. Indeed, incre-
ased minimal inhibitory concentrations of daptomycin have been 
associated with treatment failure in other countries [20]. 
Resistance to third- and fourth-generation cephalosporins in 
E. coli has increased since 2004 (Fig. 1). The resistance rate to 
cefotaxime was slightly higher than that to ceftazidime, which is 
consistent with a previous report on the dissemination of CTX-M 
type extended spectrum β-lactamase (ESBL) rather than TEM- 
or SHV- type ESBL [21]. As fluoroquinolone-resistant E. coli also 
increased to 48%, the empirical use of fluoroquinolone for uri-
nary tract infections caused primarily by E. coli should be avoided, 
as previously reported [22]. The reason underlying the continual 
increase in fluoroquinolone resistance is unclear; it might be re-
lated to mutation of the gyrase or topoisomerase IV genes inclu-
ding qyrA, gyrB, parC and parE [23]. Moreover, the spread of 
plasmid-mediated fluoroquinolone-resistance, such as the qnr 
gene, should also be considered [24]. Further evaluations are 
required to determine the mode of resistance. Interestingly, only 
the resistance rate to cefoxitin decreased to 9%. This finding 
might indicate the reduced prevalence of plasmid-mediated AmpC 
β-lactamase genes, such as DHA-1 and CMY-1 [25], due to low-
ered selective pressure for cephamycin. In K. pneumoniae, the 
resistance rates to most antimicrobial agents, including third- 
and fourth-generation cephalosporins and fluoroquinolone, re-
mained similar to previous results, except for decreased resis-
tance to cefoxitin. The rates in CRE remained at <1% in 2015; 
however, the susceptibility rates to carbapenem (especially me-
ropenem) in Enterobacteriaceae, including E. coli and K. pneu-
moniae, decreased from 100% and 99.3 in 2011 to 99.0% and 
97.0% in 2015, respectively. Furthermore, carbapenem non-
susceptible E. coli were reported in 75.0% of hospitals in 2015, 
which was higher than in 2013 (43.8%), and carbapenem non-
susceptible K. pneumoniae were reported in all participating hos-
pitals from 2013 to 2015. Therefore, appropriate surveillance 
using rapid detection and infection control strategies for CRE 
should be mandated to prevent the spread of CRE, especially 
carbapenemase-producing organisms. Furthermore, molecular 
genetic studies of multidrug-resistant Enterobacteriaceae should 
be conducted to elucidate the mechanisms of resistance and 
dissemination.
P. aeruginosa and A. baumannii are important pathogens in 
healthcare-associated infections. The emergence of multidrug-
resistant P. aeruginosa and multidrug-resistant A. baumannii is 
a major concern in Korea, because few drugs, except for poly-
myxins, are available for the treatment of these infections. The 
incidence of carbapenem-resistant P. aeruginosa was 35% in 
2015, higher than the rate reported by Lee et al in 2009 (23%) 
[4]. Surprisingly, the resistance rates of P. aeruginosa to third- 
and fourth-generation cephalosporins, amikacin, and gentami-
cin decreased significantly with the increased resistance rate to 
carbapenem, similar to observations in France from the last 4 
years; however, the mechanism underlying this phenomenon 
remains unclear [11]. Another remarkable change in P. aerugi-
nosa carbapenem resistance is the emergence of ST235 bear-
ing the IMP-6 metallo-β-lactamase since the early 2010s. Al-
though the reason for the transition from the VIM-2 to IMP-6 
phenotype is not clear [26, 27], the increased use of merope-
nem may be associated with the dissemination of IMP-6, be-
cause IMP-6 can hydrolyze meropenem more efficiently than 
VIM-2 [28]. In addition, the rate of carbapenem-resistant A. bau-
mannii gradually increased to >80%. This finding can be ex-
plained by the horizontal spread of A. baumannii carrying the 
blaOXA-23-like gene, which is the most common type of carbape-
nem resistance in Korea [29]. In contrast, the resistance rate to 
ampicillin-sulbactam decreased to 46% in 2015. Therefore, am-
picillin-sulbactam could constitute a treatment option for MRAB 
in combination with colistin [30]. The resistance rate of A. bau-
mannii to tigecycline remained at <5% in 2015, when the break-
point for Enterobacteriaceae was applied. However, several stud-
ies have demonstrated the inefficacy of tigecycline for the treat-
ment of MRAB because of rapid distribution to the tissue, which 
results in increased all-cause mortality [31].
In conclusion, we analyzed KARMS data from 16 hospitals 
from 2013 to 2015 with respect to antimicrobial resistance trends. 
The resistance rate of E. coli to third- and fourth-generation ceph-
alosporins and fluoroquinolone increased significantly and car-
bapenem-non-susceptible Enterobacteriaceae are becoming a 
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more common clinical isolate. The prevalence of carbapenem-
resistant P. aeruginosa and A. baumannii increased significantly, 
leaving few remaining treatment options for these infections. Fur-
thermore, nationwide antimicrobial susceptibility surveillance 
should be improved in order to standardize the quality of data 
and meet global needs. 
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